Regenerative implant producer OssDsign, based on research at Karolinska University Hospital and Uppsala University, hopes to list on the Nasdaq First North and raise $15.8m.

Exosome therapeutics developer Codiak BioSciences, exploiting technology developed by researchers at the universities of Gothenburg and Texas, is eyeing up to $86.3m in an IPO.

Cambridge Innovation Capital is in line for an exit as oncology drug developer Bicycle Therapeutics prepares to float, having filed to raise $86m in its IPO.

Willow Biosciences is the result of a three-way merger between University of Calgary spinout Epimeron, BioCan Technologies and CSE-listed Makena Resources.

The Oxford University genetic sequencing spinout is reportedly mulling an IPO that would provide exits to investors including commercialisation firm IP Group.

The corporate-backed genome editing technology developer Precision BioSciences, which was spun out of Duke University, floated in the middle of its range and is now valued at more than $780m.

Genomic medicine developer Precision Biosciences plans to raise up to $100m in an upcoming IPO that could hand exits to Duke University and corporates Amgen, EMS and Baxter.

Rare disease diagnosis technology developer Centogene is gearing up for an IPO having spun out from Rostock in 2006 and raised $28.5m of equity funding in 2017.

VetMedUni biopharmaceutical spinout Marinomed Biotech has completed its IPO to attain a market cap of $109m.

Rob Lavine, News editor for Global Corporate Venturing, reviews the trends in venturing from 2018